The effect of differing gleason scores at biopsy on the odds of upgrading and the risk of death from prostate cancer

Clinical Genitourinary Cancer

Volumn 12, Issue 5, 2014, Pages e181-e187

  Phillips, John G ^a   Aizer, Ayal A ^a   Chen, Ming Hui ^b   Zhang, Danjie ^b   Hirsch, Michelle S ^a   Richie, Jerome P ^a   Tempany, Clare M ^a   Williams, Stephen ^a   Hegde, John V ^c   Loffredo, Marian J ^a   D'Amico, Anthony V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

ComboGS; Pathology; Prognostic factors; Prostate cancer specific mortality; Radical prostatectomy

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; COMBOGS; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE DISTRIBUTION; RISK ASSESSMENT; BIOPSY; BLOOD; CANCER GRADING; MORTALITY; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC; TREATMENT OUTCOME;

BIOPSY; HUMANS; MALE; NEOPLASM GRADING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; ROC CURVE; TREATMENT OUTCOME;

EID: 84922658718     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.02.008     Document Type: Article

References (30)

1. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966; 50:125-8
2. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA 2009; 302:1202-9
3. D?Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280:969-74
4. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277:1445-51
5. Crook J, Ots AF. Prognostic factors for newly diagnosed prostate cancer and their role in treatment selection. Semin Radiat Oncol 2013; 23:165-72
6. Capitanio U, Karakiewicz PI, Jeldres C, et al. The probability of Gleason score upgrading between biopsy and radical prostatectomy can be accurately predicted. Int J Urol 2009; 16:526-9
7. Fu Q, Moul JW, Banez LL, et al. Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer. Med Oncol 2012; 29:3339-44
8. Hong SK, Han BK, Lee ST, et al. Prediction of Gleason score upgrading in lowrisk prostate cancers diagnosed via multi (> or = 12)-core prostate biopsy. World J Urol 2009; 27:271-6
9. Kulkarni GS, Lockwood G, Evans A, et al. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer 2007; 109:2432-8
10. Bowes D, Crook JM, Wallace K, et al. Results of a surgically derived nomogram to predict Gleason score upgrading applied to a cohort of patients with "favorable-risk" prostate cancer treated with permanent seed brachytherapy. Urology 2012; 80:649-55
11. Magheli A, Hinz S, Hege C, et al. Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience. J Urol 2010; 183:126-31
12. Turley RS, Hamilton RJ, Terris MK, et al. Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: results from the SEARCH database. J Urol 2008; 179:523-7, discussion 527-8
13. D?Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292:821-7
14. El Hajj A, Ploussard G, de la Taille A, et al. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS). BJU Int 2013; 111:53-9
15. Krane LS, Menon M, Kaul SA, et al. Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer. Urol Oncol 2011; 29:372-7
16. Reese AC, Cowan JE, Brajtbord JS, Harris CR, Carroll PR, Cooperberg MR. The quantitative Gleason score improves prostate cancer risk assessment. Cancer 2012; 118:6046-54
17. Whitson JM, Porten SP, Cowan JE, Simko JP, Cooperberg MR, Carroll PR. Factors associated with downgrading in patients with high grade prostate cancer. Urol Oncol 2013; 31:442-7
18. Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A, eds. AJCC Cancer Staging Manual. 7th edition. New York, Dordrecht, Heidelberg, London: Springer; 2009
19. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-42
20. Agresti A. Inference for Contingency Tables, Categorical Data Analysis. 2nd edition. New York: John Wiley & Sons; 2002
21. Hollander M, Wolfe D. The two-sample location problem. In: Nonparametric Statistical Methods. New York: John Wiley & Sons; 1999:106-40
22. Agresti A. Logistic regression. In: Categorical Data Analysis. Hoboken, NJ: John Wiley & Sons; 2002:165-210
23. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44:837-45
24. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94:496-509
25. Gaynor J, Feuer E, Tan C, et al. On the use of cause-specific failure andconditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc 1993; 88:400-9
26. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 1:1141-54
27. Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 2012; 61:1019-24
28. Elabbady AA, Khedr MM. Extended 12-core prostate biopsy increases both the detection of prostate cancer and the accuracy of Gleason score. Eur Urol 2006; 49: 49-53, discussion 53
29. Olmos D, Brewer D, Clark J, et al. Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol 2012; 13:1114-24
30. Ross RW, Galsky MD, Scher HI, et al. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol 2012; 13:1105-13.